Tuesday, September 26, 2023 9:44:15 AM
BENZINGA
34 mins ago
Soleno Therapeutics Inc (NASDAQ:SLNO) released top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for Prader-Willi syndrome (PWS).
PWS is a genetic disorder that causes obesity, intellectual disability, and shortness of height. It is characterized by constant craving for food.
The primary endpoint was the change from baseline in hyperphagia (extreme, insatiable hunger)-related behaviors as assessed by the hyperphagia questionnaire for clinical trials (HQ-CT).
Secondary endpoints included investigator assessments of participants' overall severity of illness and change in condition, as measured by Clinical Global Impression of Severity (CGI-S) and Clinical Global Impression of Improvement (CGI-I) ratings, respectively.
Hyperphagia-related behaviors markedly worsened in the placebo group compared to DCCR, represented by a statistically significant, clinically meaningful difference in mean change from baseline in the HQ-CT total score of 5.0 at week 16 (p=0.0022).
Secondary endpoints of CGI-S and CGI-I showed strong trends towards worsening in the placebo group compared to DCCR over the randomized withdrawal period (p=0.08 and 0.09), respectively.
DCCR continued to be generally well-tolerated.
Price Action: SLNO shares are up 409.3% at $22.18 during the premarket session on the last check Tuesday.
Recent SLNO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:31:17 PM
- Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/09/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 09:28:56 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/06/2024 08:58:44 PM
- Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock • GlobeNewswire Inc. • 05/03/2024 02:32:12 AM
- Soleno Therapeutics Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 05/02/2024 08:01:37 PM
- Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/19/2024 08:05:00 PM
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/08/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:06:32 AM
- Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results • GlobeNewswire Inc. • 03/06/2024 09:05:00 PM
- Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/31/2024 09:19:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 09:57:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 10:47:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 10:44:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 10:42:33 PM
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/29/2024 09:05:00 PM
- Soleno Therapeutics Strengthens Leadership Team with Key Appointments • GlobeNewswire Inc. • 01/24/2024 01:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/17/2024 09:06:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 10:37:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 10:35:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 10:34:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:16:02 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM